Matches in Nanopublications for { ?s ?p "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_provenance.
- NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP576837.RA9m43fnUR-yVp44WnPsJhYNuQsh9gOA80uHj1YgsneEo130_provenance.
- NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP501721.RA1w30c8tc4vFMAaC3eQisUvIjMx5a14QrE8G9S8SsULE130_provenance.
- assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP501720.RAFgLC2HDstowFeSVyIBxW2CyHVa8LCAN-JMEJrZMzwSQ130_assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP501720.RAFgLC2HDstowFeSVyIBxW2CyHVa8LCAN-JMEJrZMzwSQ130_provenance.
- NP577111.RAm8SX_t-pmrbDNRSfe9DqW2wnb3SWU48b_Iy9cPe37-k130_assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP577111.RAm8SX_t-pmrbDNRSfe9DqW2wnb3SWU48b_Iy9cPe37-k130_provenance.